choroidal neovascularisation
Intravitreal ranibizumab injection for the treatment of choroidal neovascularisation secondary to pathological myopia
College Statement The Royal College of Ophthalmologists welcomes the decision by The National Institute for Health and Care Excellence (NICE) to recommend Ranibizumab 0.5 mg intravitreal injection as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia. Prior to this decision there has been limited / variable access to anti-VEGF